西罗莫司联合环孢素与吗替麦考酚酯预防HLA抗原错配异基因移植的GVHD
该试验评估西罗莫司联合环孢素(CSP)与吗替麦考酚酯(MMF)在HLA I或II类错配非清髓性造血细胞移植(HCT)后预防移植物抗宿主病(GVHD)的疗效。77例患者入组,76例完成干预,中位随访47个月。第100天2-4级急性GVHD累积发生率为36%(95%CI 25-46),达到主要终点。
要点
- 西罗莫司联合CSP与MMF使HLA错配HCT后第100天2-4级急性GVHD累积发生率为36%(95%CI 25-46)。
- 4年非复发死亡率18%(95%CI 9-27),复发/进展30%(四分位距19-40),总生存62%(95%CI 50-73)。
- 作者认为加用西罗莫司降低了急性GVHD发生率,相比历史结果转化为更优的总生存。
核心结论
- 作者认为,在环孢素与吗替麦考酚酯基础上加用西罗莫司降低了急性GVHD发生率,相比历史结果转化为更优的总生存。
研究设计与样本
- 该试验为评估西罗莫司联合环孢素与吗替麦考酚酯用于HLA I或II类错配非清髓性造血细胞移植后GVHD预防的干预性研究。
- 2011年4月14日至2018年12月12日共招募77例可经异基因HCT治疗的血液系统恶性肿瘤患者,其中76例完成研究干预,研究于2018年12月20日关闭。
- 预处理方案为氟达拉滨(90 mg/m2)联合2至3 Gy全身照射。
- GVHD预防方案包括环孢素、吗替麦考酚酯和西罗莫司。
- 主要目标为确定HLA I或II类错配HCT后2至4级急性GVHD累积发生率能否降至<70%。
主要发现
- 中位随访47个月(范围4-94个月)。
- 第100天2至4级急性GVHD累积发生率为36%(95%CI 25-46),达到主要终点。
- 4年非复发死亡率累积发生率为18%(95%CI 9-27)。
- 4年复发/进展累积发生率为30%(四分位距19-40)。
- 4年总生存率为62%(95%CI 50-73)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This trial aimed to evaluate the efficacy of sirolimus in addition to cyclosporine (CSP) and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis after nonmyeloablative conditioning for HLA class I or II mismatched hematopoietic cell transplantation (HCT). Eligible patients had hematologic malignancies treatable by allogeneic HCT. Conditioning consisted of fludarabine (90 mg/m2) and 2 to 3 Gy total body irradiation. GVHD prophylaxis comprised cyclosporine, mycophenolate mofetil, and sirolimus. The primary objective was to determine whether the cumulative incidence of grade 2 to 4 acute GVHD could be reduced to <70% in HLA class I or II mismatched HCT. The study was closed on December 20, 2018. Seventy-seven participants were recruited between April 14, 2011, and December 12, 2018, of whom 76 completed the study intervention. Median follow-up was 47 months (range, 4-94 months). The cumulative incidence of grade 2 to 4 acute GVHD at day 100 was 36% (95% confidence interval [CI], 25-46), meeting the primary end point. The cumulative incidence of nonrelapse morality, relapse/progression, and overall survival was 18% (95% CI, 9-27), 30% (interquartile range, 19-40), and 62% (95% CI, 50-73) after 4 years. In conclusion, the addition of sirolimus to cyclosporine and mycophenolate mofetil resulted in a lower incidence of acute GVHD, thus translating into superior overall survival compared with historical results. This trial was registered at www.clinicaltrials.gov as #NCT01251575.
引用
- Kornblit B, Storer BE, Andersen NS, et al. Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors. Blood. 2020. PMID: 32603426. doi:10.1182/blood.2020005338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。